Match Document Document Title
US20150184146 Formulation for Oral Administration of Proteins  
Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and GI tract by the addition of an antioxidant.
US20110171315 Oral recombinant helicobacter pylori vaccine and preparing method thereof  
The invention relates to a recombinant protein used for immunoprophylaxis of human Helicobacter pylori infection and a degradable slow-releasing microsphere-encapsulated oral vaccine preparation...
US20110263487 Plant Production and Delivery System for Recombinant Proteins as Protein-Flour or Protein-Oil Compositions  
The present invention relates to a plant flour material comprising a ground, dried plant material, wherein the plant material contains a recombinant protein comprises a bactericidal or an...
US20150185232 INNATE IMMUNE PROTEINS AS BIOMARKERS FOR CNS INJURY  
The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein...
US20130058891 Kexin-Derived Vaccines to Prevent or Treat Fungal Infections  
A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat...
US20140220106 LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS  
Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
US20110212162 LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS  
Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
US20140178350 DEPHOSPHORYLATED LYSOSOMAL STORAGE DISEASE PROTEINS AND METHODS OF USE THEREOF  
Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having...
US20110217732 METHOD AND COMPOSITIONS FOR THE DETECTION OF PROTEIN GLYCOSYLATION  
The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations....
US20130183712 METHOD AND COMPOSITIONS FOR THE DETECTION OF PROTEIN GLYCOSYLATION  
The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations....
US20140162340 SYNTHETIC HEPATITIS C GENOME AND METHODS OF MAKING AND USE  
Synthetic representative HCV subtypes, including a 1a and 1b genome, dubbed Bole1a and Bole1b, are provided using an inventive method of Bayesian phylogenetic tree analysis, ancestral sequence...
US20110183863 PROTEIN SCREENING METHODS  
The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro.
US20110223240 COMPOUNDS FOR REVERSING AND INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM  
The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods...
US20120328591 METHODS FOR IMPROVING ORAL DELIVERY  
The invention provides a method of improving the oral delivery of a therapeutic agent, comprising the step of linking the therapeutic agent to a carrier protein comprising angiogenin, fusion...
US20140296181 METHODS OF MODULATING ONCOGENIC FUSION PROTEINS  
Described herein, at least in part, are methods of modulating oncogenic fusion proteins.
US20140272964 Blue Fluorescent Protein and Methods of Use Thereof  
This invention provides methods of making and using a fluorescent probe from the Sandercyanin protein as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. In one embodiment, the invention provides a...
US20140194595 Method and Composition for Crystallizing G Protein-Coupled Receptors  
Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion...
US20130216479 SITE-SPECIFIC CHEMICAL MODIFICATION OF PROTEINS AT THEIR N-TERMINI, ENABLING THE FORMATION OF HOMOGENEOUS ADDUCTS  
Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous...
US20120244137 Method of Purifying Pegylated Proteins  
The invention relates to a method of purifying PEGylated proteins by removing impurities from samples containing PEGylated proteins, in particular, but not exclusively vitamin K-dependent blood...
US20130323220 TAL-Tet1 Fusion Proteins and Methods of Use Thereof  
Fusion proteins comprising a DNA binding domain, e.g., a TAL effector repeat array or zinc finger, and a catalytic domain comprising a sequence that catalyzes hydroxylation of methylated cytosines...
US20150118730 ENZYME-BASED PROTEIN SEPARATION AND ENRICHMENT FROM SOY MEAL, WHEAT MEAL, AND OTHER PROTEIN-RICH MATERIALS DERIVED FROM PLANT SEEDS, FRUITS AND OTHER BIOMASS  
The present invention is directed to enzyme based methods for separating protein from protein-rich materials derived from plant seeds, fruit, or other biomass and products made therefrom. The...
US20130336946 FUSION PROTEINS AND METHODS FOR TREATING HIV INFECTION AND AIDS RELATED SYMPTOMS  
The present invention discloses pharmaceutical compositions and methods for using a fusion protein comprising a superoxide dismutase and a transit peptide. The present invention also discloses...
US20150087044 POLYHEDRAL CAGE-CONTAINING MESOPOROUS METAL-ORGANIC FRAMEWORKS AS PLATFORM FOR BIOCATALYSIS, METHODS OF MAKING THESE FRAMEWORKS, AND METHODS OF USING THESE FRAMEWORKS  
Embodiments of the present disclosure provide compositions including polyhedral mesoporous metal-organic framework including a biomolecule (e.g., enzyme), methods of making these compositions,...
US20130330368 EYE DROP COMPOSITION FOR PREVENTION AND TREATMENT OF OPHTHALMIC DISEASES CONTAINING FUSION PROTEIN OF FK506 BINDING PROTEIN  
Disclosed is a treatment for ophthalmic diseases, more specifically, a pharmaceutical composition for treating ophthalmic diseases including a fusion protein of FK506 binding protein capable of...
US20150079095 PREVENTON, TREATMENT AND DIAGNOSIS OF P. GINGIVALIS INFECTION  
The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.
US20110280880 PREVENTION, TREATMENT AND DIAGNOSIS OF P.GINGIVALIS INFECTION  
The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.
US20150044772 CRISPR/CAS SYSTEM-BASED NOVEL FUSION PROTEIN AND ITS APPLICATIONS IN GENOME EDITING  
An inactive CRISPR/Cas system-based fusion protein and its applications in gene editing are disclosed. More particularly, chimeric fusion proteins including an inCas fused to a DNA modifying...
US20150203837 FUSION PROTEIN FOR ACTIVATING RTK SIGNAL TRANSMISSION BY MEANS OF LIGHT, AND USE THEREOF  
The present invention relates to a fusion protein for reversibly activating RTK signal transmission by means of light and relates to a use thereof, and the invention provides a fusion protein in...
US20120009593 ANALYSIS METHOD FOR THE IN VITRO DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN DOGS BY ASSAYING CANINE PROSTATE SPECIFIC ESTERASE, AND BPH TREATMENT FOLLOW UP  
The invention relates to an analysis method for the in vitro diagnosis of benign prostatic hyperplasia (BPH) in a dog, using the CPSE contained in biological fluid samples collected from the dog...
US20120270797 ENGINEERED PROTEINS INCLUDING MUTANT FIBRONECTIN DOMAINS  
The present invention features engineered proteins that can include a genetically modified Fn domain; two or more such domains joined to one another; or at least one genetically modified Fn domain...
US20110104782 CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF  
The present invention provides crystalline molecules or molecular complexes which comprise binding pockets of Aurora-2 or its homologues. The invention also provides crystals comprising Aurora-2....
US20110177527 METHODS AND COMPOUNDS FOR TESTING BINDING OF A LIGAND TO A G PROTEIN-COUPLED RECEPTOR  
The present invention relates to compounds and methods for testing for the binding of a ligand to a G Protein-Coupled Receptor. In particular, the compounds of the invention are useful in high...
US20130004504 METHOD OF MODULATING PHENYLALANINE HYDROXYLASE STRUCTURE AND FUNCTION  
A method of affecting a multimeric protein comprising an equilibrium of assembly states, each assembly having a plurality of units, wherein each of the units comprises a first complementary...
US20140127718 IDENTIFICATION OF SECRETED PROTEINS AS DETECTION MARKERS FOR CITRUS DISEASE  
Secreted proteins as detection markers for insect vector and graft transmitted citrus disease are described. Method and kits for detecting the secreted proteins are provided.
US20140356281 DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17  
Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
US20140271458 DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17  
Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
US20120021440 METHODS FOR TESTING LIGAND BINDING TO G PROTEIN-COUPLED RECEPTORS  
The present invention relates to methods for testing for the binding of a ligand to a G Protein-Coupled Receptor. In particular, the methods of the invention are useful in high throughput...
US20110201021 USE OF THE IRAP PROTEIN FOR IMPLEMENTING METHODS OF DIAGNOSIS AND OF PROGNOSIS  
The use of the IRAP protein for implementing methods of diagnosis and of prognosis.
US20110008455 Crosslinked Protein Nanocrystals, Crosslinked Protein Nanoaggregates and Method of Preparation Thereof  
This invention relates to crosslinked protein nanoparticles and a method for producing the same. The method comprises the preparation and nanonization (i.e., size reduction to the nanoscale) of...
US20110039277 Methods of Labeling Proteins  
Methods are provided for labeling specific oxidized proteins. Methods also are provided for determining the oxidation state of a cell. Such methods are useful as diagnostic, therapeutic and...
US20100303723 DRUG DELIVERY SYSTEMS USING FC FRAGMENTS  
The present invention provides drug delivery systems comprising FcRn binding partners (e.g., FcRn binding partner, Fc fragment) associated with a particle or an agent to be delivered. Inventive...
US20130130347 CONSTRUCTS AND METHODS FOR THE ASSEMBLY OF BIOLOGICAL PATHWAYS  
The present invention is directed to a synthetic nucleic acid scaffold comprising one or more subunits, each subunit comprising two or more different protein-binding sequences coupled together....
US20130059359 Protein Nanorings  
The invention provides protein nanorings.
US20140186494 Pregastric Esterase and Derivatives Thereof  
The present invention relates to novel lipase polynucleotide sequences, their corresponding proteins as well as ways of manufacturing said sequences and said proteins and use of the proteins in...
US20130252306 METHODS FOR INCREASING PROTEIN POLYETHYLENE GLYCOL (PEG) CONJUGATION  
The present invention relates to highly conjugated proteins and methods for making such proteins. In particular, the present invention relates to methods for linking additional sites to a protein...
US20150152402 METHOD OF PRODUCING RECOMBINANT PROTEINS WITH MANNOSE-TERMINATED N-GLYCANS  
We describe a method of expressing a recombinant protein comprising mannose-terminated N-glycans from a host cell, the method comprising: (a) introducing a nucleic acid encoding a recombinant...
US20110250215 STRUCTURALLY-RELATED RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES  
Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion...
US20100303787 Methods of Treating Urogenital-Neurological Disorders Using Galanin Retargeted Endopepidases  
The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions.
US20120190096 MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN  
The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water...
US20120270296 ISOTOPE-DOPED NANO-STRUCTURE AND ISOTOPE LABELED STRUCTURE USING THE SMAE  
An isotope-doped nano-structure is provided. The isotope-doped nano-structure includes at least one isotope-doped nano-structure segment having at least two isotopes of the element. The at least...